Additional Relevant Details From the Q4 Earnings Transcript: "Our strategic plan is to secure a commercial partnership with arhalofenate prior to the start of our Phase 3 program. Gout, as you know, is predominately treated by primary care physicians. Therefore, partnering arhalofenate with one or more companies that have a presence in the primary care market is a priority for us."  CymaBay, according to a press release, is in ongoing discussions with potential partners.